# The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB)

> **NCT06476210** · PHASE4 · RECRUITING · sponsor: **Beijing Chest Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Pulmonary Tuberculosis

## Interventions

- **DRUG:** BDL regimen

## Key facts

- **NCT ID:** NCT06476210
- **Lead sponsor:** Beijing Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06
- **Primary completion:** 2025-06
- **Final completion:** 2026-06
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2024-06-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06476210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06476210, "The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB)". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT06476210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*